Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback